同和药业(300636) - 同和药业调研活动信息

Group 1: Shareholder Actions - Major shareholders reduced their holdings through block trades, totaling 859,000 shares, with transaction prices significantly lower than market expectations [2][3] - The block trades occurred on October 28, 29, and November 4, 2020, with prices at 25.54, 24.97, and 24.73, respectively, leading to a perception of low-price selling [2][3] - The purpose of the reduction was to separate partnership shares into individual names, as required by regulations [2] Group 2: Patent Expirations and Product Development - Key patents expiring in the coming years include: - Ticagrelor: US, South Korea, Brazil in July 2021; Europe in May 2021; Japan in August 2025 - Rivaroxaban: Europe in December 2020 and October 2023; South Korea in October 2021 - Dabigatran: US, Brazil in December 2021; Europe, Japan in February 2023 - Mirabegron: US, Brazil in March 2022; Europe, Japan in October 2023 [3] - The company is enhancing production capacity to avoid gaps due to patent expirations and is focusing on domestic sales of raw materials [4] Group 3: Market Position and Future Outlook - The company holds a strong competitive position in the specialty raw materials market, with significant advantages in scale, quality, and market expansion capabilities [5][6] - The global market for the product Ticagrelor reached over 100 tons in 2019, with an expected total of around 550 tons from 2022 to 2024, indicating a promising growth trajectory [6] - The company anticipates a sales revenue of 700-800 million CNY from its first plant at full capacity, with a peak output value expected in 2021-2022 [8] Group 4: Product Performance and Industry Trends - The company is a major supplier of Gabapentin, Rivaroxaban, and Celecoxib, with Rivaroxaban accounting for approximately 50% of the global market consumption [7] - Future sales of Gabapentin and Celecoxib are expected to increase significantly, driven by cost reductions and process optimizations [7] - The company aims to ensure that more products rank among the top three in their respective global segments [7]